Navigation Links
Researchers find function of proteins that can enhance the progression of viruses and cancer cells

In a discovery that has implications for developing treatments against cancer and potentially deadly viruses, researchers at SUNY Downstate Medical Center have discovered the function of proteins that can enhance the progression of certain viruses and cancer cells. Their findings were published in the journal Genes and Development.

According to Tatyana Pestova, PhD, DSc, assistant professor of cell biology, and Christopher Hellen, DPhil, associate professor of cell biology, "The significance of our work is that we have identified proteins (Ligatin, MCT-1 and DENR) that can substitute for the activity of one or more canonical initiation factors in the initiation and ribosome recycling stages of eukaryotic protein synthesis. These factors act either individually (Ligatin) or together (MCT-1 and DENR) to substitute for eIF2 in promoting initiation of translation on a specific subset of mRNAs under conditions when translation is globally repressed. These observations are clinically relevant with respect to (a) viral infections and (b) cancer pathogenesis." Maxim Skabkin, PhD, a research scientist in the Department of Cell Biology, is the lead author of the paper.

The cellular response to counteract viral infection involves activation of pathways that "shut off" translation by phosphorylating eIF2, preventing it from recruiting initiator tRNA to the ribosome. Some viral mRNAs continue to be translated at the same or a reduced rate under these conditions, including those of Hepatitis C virus, human rotaviruses (a major cause of acute, frequently fatal, gastroenteritis in infants), coronaviruses (including SARS), and alphaviruses (e.g. Sindbis virus).

The authors reported a novel eIF2-independent mode of translation initiation in which Ligatin alone or MCT-1 and DENR together promote binding of initiator tRNA to specific ribosomal initiation complexes, and found that this mechanism functions very efficiently for Sindbis virus and to a lesser extent for Hepatitis C virus and related pathogenic viruses. This novel initiation mechanism is thus a potential target for therapeutic inhibition to counteract viral infection.

This eIF2-independent mode of initiation is likely a cellular mechanism that has been co-opted by viruses. MCT-1 (multiple copies in T-cell lymphoma-1) has previously been reported to act at the translational level to increase cell proliferation and survival and to enhance the invasiveness of cancer cells, but how it functions was not known. It is an oncogene that is over-expressed in lung cancer tissues and has been implicated in the development of human T-cell and B-cell lymphomas.

Dr. Hellen adds, "Our identification of a specific role for MCT-1 in promoting eIF2-independent initiation on specific mRNAs could account for its oncogenic activity by promoting the preferential translation of a subset of cancer-related mRNAs into proteins that promote angiogenesis, tumor cell survival, transformation, and metastasis."


Contact: Ron Najman
SUNY Downstate Medical Center

Related medicine news :

1. In NIH-funded study, researchers uncover step in brain events leading up to addiction
2. Researchers develop magnetic molecular machines to deliver drugs to unhealthy cells
3. UCLA researchers discover protein that shuttles RNA into cell mitochondria
4. Help wanted: Highly cited researchers needed for high-ranking positions at research institutions
5. NIST researchers measure high infrared power levels from some green lasers
6. Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts
7. Researchers develop advanced search tool to help physicians sort and retrieve vital EMR data
8. Researchers identify key enzyme in DNA repair pathway
9. Researchers study benefits of white button mushrooms
10. Use of decision-aid program increases safety for women experiencing abuse, researchers find
11. Researchers uncover biological rationale for why intensive lupus treatment works
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Insightra Medical, Inc. and Novus Scientific AB ... soft tissue repair in the US via Insightra’s national direct sales channel. , ... to support and reinforce soft tissue for 6-9 months before absorbing completely after ...
(Date:11/30/2015)... Viejo, CA (PRWEB) , ... November 30, 2015 , ... ... Cut Pro X . Choose from scrolling web-styled transitions to wipes with blur ... colors, transition direction and more. Seamlessly transition from one clip to the next ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation solutions provider ... 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. The addition ... industrial, manufacturing and government workers and organizational leaders that are introduced to innovative ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas for ... Beauty NATURALS®. All products are available on Amazon or its webstore. , "We ... serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy Heshelow, ...
(Date:11/29/2015)... ... November 29, 2015 , ... Khanna Vision Institute based ... of Ophthalmology on November 25th 2015. Peer Certification by the Board is done ... specialty. Certification in Ophthalmology is first obtained after the completion of three years of ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)...  The GE Health Cloud 1 was unveiled today ... North America (RSNA) meeting in ... new cloud ecosystem and its applications will connect radiologists and ... multidisciplinary teams – both inside and outside the hospital setting. ... GE. "As the digital industrial leader, we are betting big ...
(Date:11/27/2015)... 27, 2015 Ein neuer ... Krebs.   --> Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz ...   Clinical Cancer Research vom ... Cancer Research vom 6. November 2015 berichtet. ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
Breaking Medicine Technology: